Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
November 6, 2015 6:53 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they maintain high conviction in Eteplirsen approval.
Messer commented, "SRPT shares have pulled back from recent highs due to concerns that etelpirsen's later than expected... More
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c
November 5, 2015 7:04 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.11), $0.07 better than the analyst estimate of ($1.18).
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More